Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 62 of the 72 references it cites were found in a registry or an index; 20 of the 23 sources its claims cite were checked for support.

Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population

Open access

Abstract

The SARS-CoV-2 Omicron variant has demonstrated enhanced transmissibility and escape of vaccine-derived immunity. Although first-generation vaccines remain effective against severe disease and death, robust evidence on vaccine effectiveness (VE) against all Omicron infections, irrespective of symptoms, remains sparse. We used a community-wide serosurvey with 5,310 subjects to estimate how vaccination histories modulated risk of infection in infection-naive Hong Kong during a large wave of Omicron BA.2 epidemic in January-July 2022. We estimated that Omicron infected 45% (41-48%) of the local population. Three and four doses of BNT162b2 or CoronaVac were effective against Omicron infection 7 days after vaccination (VE of 48% (95% credible interval 34-64%) and 69% (46-98%) for three and four doses of BNT162b2, respectively; VE of 30% (1-66%) and 56% (6-97%) for three and four doses of CoronaVac, respectively). At 100 days after immunization, VE waned to 26% (7-41%) and 35% (10-71%) for three and four doses of BNT162b2, and to 6% (0-29%) and 11% (0-54%) for three and four doses of CoronaVac. The rapid waning of VE against infection conferred by first-generation vaccines and an increasingly complex viral evolutionary landscape highlight the necessity for rapidly deploying updated vaccines followed by vigilant monitoring of VE.

Overview

CoChat Summary

TL;DR

In infection-naive Hong Kong during the January–July 2022 Omicron BA.2 wave, a community-wide serosurvey estimated that 45% (41–48%) of the population was infected. Three and four doses of BNT162b2 or CoronaVac were effective against Omicron infection shortly after vaccination, but VE waned substantially by 100 days.

Key findings

  • Omicron infected 45% (41–48%) of the population; overall ascertainment was 25% (23–27%) by RT–PCR alone and 41% (38–45%) with rapid antigen testing. Population immunity reached 52% (45–57%) by 31 July 2022.
  • VE against infection 7 days after a third or fourth dose was 48% (34–64%) and 69% (46–98%) for BNT162b2, and 30% (1–66%) and 56% (6–97%) for CoronaVac, respectively.
  • At 100 days after immunization, VE waned to 26% (7–41%) and 35% (10–71%) for three and four BNT162b2 doses, and to 6% (0–29%) and 11% (0–54%) for three and four CoronaVac doses.
  • The study reports the first real-world estimates of VE and waning against Omicron infection for three or four doses of CoronaVac; its ORF8 assay was described as the first serological test able to discriminate recent SARS-CoV-2 infection from vaccination among CoronaVac vaccinees.

Methods

  • Community-wide serosurvey of 5,310 subjects: 5,173 healthy adult blood donors recruited 28 April–30 July 2022 and 137 children aged 18 months–11 years from an independent polio seroepidemiology study. Vaccination histories were available for 5,242 subjects from Hong Kong Department of Health records (98%) or self-report (2%).
  • Two in-house ELISAs detected IgG to SARS-CoV-2 N-CTD and ORF8; a Bayesian model inferred each subject’s probability of prior infection from age, vaccination record, and seropositivity. The force of infection was assumed proportional to city-wide wastewater viral load, and VE was defined as reduction in infection probability relative to unvaccinated individuals, assuming a 7-day delay to full effect and exponential waning.
  • Estimated VE and waning were applied to anonymized population vaccination records to derive age-specific infection attack rates, population immunity, and ascertainment ratios; sensitivity analyses used 14- or 21-day delays, specimens collected by 15 June 2022, and different seroconversion assumptions.

Limitations

  • The paper states that it assumed vaccination history had negligible effect on contact patterns/mobility; had no sera from ages 12–17 and few from >65 years, making IAR estimates less robust for those groups; could not estimate VE against hospitalization, severe disease, or death because oral antivirals were widely introduced; relied on blood donors and voluntary child participants who may be healthier than the general population; had few CoronaVac vaccinees and a short fifth wave, causing substantial uncertainty in CoronaVac VE; could not estimate heterologous vaccination VE; used positive controls only from confirmed/self-reported infections, potentially missing asymptomatic or mild infections and underestimating IAR; and could not estimate accelerated waning due to later variants such as BA.4/BA.5.
  • Evident from the text: the serosurvey is cross-sectional, so infection timing and prior exposure are inferred rather than directly observed, and some vaccination/infection histories relied on self-report.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02219-5

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Daily COVID-19 confirmed cases, SARS-CoV-2 wastewater viral load, weekly proportion of SARS-CoV-2 lineages, population vaccination coverage, sera collection history and study subject vaccination history. a, Daily confirmed COVID-19 cases in Hong Kong stratified by cases confirmed by RT–PCR or RAT, superimposed against 2-day running geometric mean viral load per capita (in millions of copies of SARS-CoV-2 RNA l−1) detected in city-wide wastewater surveillance. b, Weekly proportion of SARS-CoV-2 lineages detected in Hong Kong via genome sequencing as uploaded to GISAID by 14 September 2022. c, Total population with one to four doses of BNT162b2 and/or CoronaVac in Hong Kong. d, Number of serum samples collected weekly. e–h, Vaccination history for study participants with one (e), two (f), three (g) and four (h) homologous doses of BNT162b2 at the time of sample collection. i–l, Vaccination history for study participants with one (i), two (j), three (k) and four (l) homologous doses of CoronaVac at the time of sample collection. The shaded areas in e–l correspond to the duration of the fifth wave from 1 January to 31 July 2022.
Fig. 1 Daily COVID-19 confirmed cases, SARS-CoV-2 wastewater viral load, weekly proportion of SARS-CoV-2 lineages, population vaccination coverage, sera collection history and study subject vaccination history. a, Daily confirmed COVID-19 cases in Hong Kong stratified by cases confirmed by RT–PCR or RAT, superimposed against 2-day running geometric mean viral load per capita (in millions of copies of SARS-CoV-2 RNA l−1) detected in city-wide wastewater surveillance. b, Weekly proportion of SARS-CoV-2 lineages detected in Hong Kong via genome sequencing as uploaded to GISAID by 14 September 2022. c, Total population with one to four doses of BNT162b2 and/or CoronaVac in Hong Kong. d, Number of serum samples collected weekly. e–h, Vaccination history for study participants with one (e), two (f), three (g) and four (h) homologous doses of BNT162b2 at the time of sample collection. i–l, Vaccination history for study participants with one (i), two (j), three (k) and four (l) homologous doses of CoronaVac at the time of sample collection. The shaded areas in e–l correspond to the duration of the fifth wave from 1 January to 31 July 2022.CC BY · PubMed Central
Fig. 2 SARS-CoV-2 N-CTD and ORF8 antibody responses among study subjects by vaccination history, age and self-reported infection history. a–c, Unvaccinated (n = 116 subjects) (a), BNT homologously vaccinated (n = 3,759 subjects) (b) and CoronaVac homologously vaccinated (n = 906 subjects) (c). Panels on the left correspond to individuals with no self-reported infection history or who did not provide their infection history. Panels on the right correspond to individuals with self-reported infection history. The blue dotted line corresponds to the OD thresholds for seropositivity (N-CTD OD of 0.2583 for unvaccinated and BNT homologously vaccinated, and ORF8 OD of 0.33 for CoronaVac homologously vaccinated). Each dot represents one study subject. The center line of each box represents the median, box limits represent the interquartile range (IQR), and the whiskers represent the minimum and maximum observations greater and lesser than the IQR plus 1.5× IQR, respectively.
Fig. 2 SARS-CoV-2 N-CTD and ORF8 antibody responses among study subjects by vaccination history, age and self-reported infection history. a–c, Unvaccinated (n = 116 subjects) (a), BNT homologously vaccinated (n = 3,759 subjects) (b) and CoronaVac homologously vaccinated (n = 906 subjects) (c). Panels on the left correspond to individuals with no self-reported infection history or who did not provide their infection history. Panels on the right correspond to individuals with self-reported infection history. The blue dotted line corresponds to the OD thresholds for seropositivity (N-CTD OD of 0.2583 for unvaccinated and BNT homologously vaccinated, and ORF8 OD of 0.33 for CoronaVac homologously vaccinated). Each dot represents one study subject. The center line of each box represents the median, box limits represent the interquartile range (IQR), and the whiskers represent the minimum and maximum observations greater and lesser than the IQR plus 1.5× IQR, respectively.CC BY · PubMed Central
Fig. 3 Estimated VE. VE at 0 to 200 days from receipt of last dose. VE is presented separately over time for two, three or four homologous doses of BNT162b2 (BNT) or CoronaVac. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.
Fig. 3 Estimated VE. VE at 0 to 200 days from receipt of last dose. VE is presented separately over time for two, three or four homologous doses of BNT162b2 (BNT) or CoronaVac. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.CC BY · PubMed Central
Fig. 4 Estimated IAR, population immunity and ascertainment ratio. a, Cumulative IAR by 31 July 2022. b, Cumulative population immunity from infection and vaccination, assuming no waning of immunity from natural infection, by 31 July 2022. c,d, Ascertainment rate based on all cumulative confirmed cases (c) or cumulative RT–PCR-confirmed cases only (d). All analyses were stratified by assumptions on delay to VE taking effect and age group. The dots indicate posterior medians and the lines indicate 95% credible intervals based on the fitted model. *Cumulative IAR, population immunity and ascertainment rate estimates among those aged 12–19 or 60 and above were less accurate because no subjects were between 12 and 17 years old, and few were above 65 years old.
Fig. 4 Estimated IAR, population immunity and ascertainment ratio. a, Cumulative IAR by 31 July 2022. b, Cumulative population immunity from infection and vaccination, assuming no waning of immunity from natural infection, by 31 July 2022. c,d, Ascertainment rate based on all cumulative confirmed cases (c) or cumulative RT–PCR-confirmed cases only (d). All analyses were stratified by assumptions on delay to VE taking effect and age group. The dots indicate posterior medians and the lines indicate 95% credible intervals based on the fitted model. *Cumulative IAR, population immunity and ascertainment rate estimates among those aged 12–19 or 60 and above were less accurate because no subjects were between 12 and 17 years old, and few were above 65 years old.CC BY · PubMed Central
Fig. 5 IAR and population immunity over time. a, IAR over time. b–d, Population immunity over time from infection and vaccination, assuming no waning of immunity from natural infection (b), immunity from infection wanes by 15% after 365 days (c) and immunity from infection wanes by 25% after 100 days (d). All analyses were stratified by assumptions on delay to VE taking effect. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.
Fig. 5 IAR and population immunity over time. a, IAR over time. b–d, Population immunity over time from infection and vaccination, assuming no waning of immunity from natural infection (b), immunity from infection wanes by 15% after 365 days (c) and immunity from infection wanes by 25% after 100 days (d). All analyses were stratified by assumptions on delay to VE taking effect. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.CC BY · PubMed Central
Fig. 6 IAR over time by age group. IAR estimates among those aged 12–19 or 60 and above were less accurate because no subjects were between 12 and 17 years old, and few were above 65 years old. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.
Fig. 6 IAR over time by age group. IAR estimates among those aged 12–19 or 60 and above were less accurate because no subjects were between 12 and 17 years old, and few were above 65 years old. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.CC BY · PubMed Central
Extended Data Fig. 1 The effect of age on force of infection (FOI) (that is f(a) in the model). Individuals aged 35 years served as the reference group. The solid line indicates the posterior median, and the shaded regions indicate the 95% credible interval based on the fitted model, differentiated by assumption on delay to vaccine effectiveness taking effect.
Extended Data Fig. 1 The effect of age on force of infection (FOI) (that is f(a) in the model). Individuals aged 35 years served as the reference group. The solid line indicates the posterior median, and the shaded regions indicate the 95% credible interval based on the fitted model, differentiated by assumption on delay to vaccine effectiveness taking effect.CC BY · PubMed Central
Extended Data Fig. 2 Use of ELISA assay to discriminate infection from vaccine immunity by vaccination cohort. This figure summarizes the in-house ELISA assays (green) we used to test for seropositivity amongst study subjects in different vaccination cohorts (orange). We did not test for seropositivity amongst heterologously vaccinated study subjects, study subjects who received vaccines other than BNT162b2 or CoronaVac, or study subjects with an un-determined vaccination history.
Extended Data Fig. 2 Use of ELISA assay to discriminate infection from vaccine immunity by vaccination cohort. This figure summarizes the in-house ELISA assays (green) we used to test for seropositivity amongst study subjects in different vaccination cohorts (orange). We did not test for seropositivity amongst heterologously vaccinated study subjects, study subjects who received vaccines other than BNT162b2 or CoronaVac, or study subjects with an un-determined vaccination history.CC BY · PubMed Central
Extended Data Fig. 3 Description of controls, assay performance and Receiver Operating Curves (ROC) by ELISA assay type for detecting Omicron infection with in-house ELISA protocols. (a) N-CTD ELISA amongst unvaccinated controls, tested against 48 unvaccinated study subjects with self-reported infection history, 142 unvaccinated RT-PCR positive convalescent samples ranging from 30 to 401 days after onset of illness and 526 pre-pandemic negative controls; (b) N-CTD ELISA amongst controls who were homologously vaccinated with BNT162b2, tested against 881 BNT-vaccinated study subjects with self-reported infection history, 1 BNT-vaccinated RT-PCR positive convalescent sample collected 369 days after onset of illness and 50 (tested twice) non-infected BNT-vaccinated samples collected during 2020–2021, a period of minimal community transmission; and (c) ORF8 ELISA amongst controls who were homologously vaccinated with CoronaVac, tested against 231 CoronaVac-vaccinated study subjects with self-reported infection history and 100 non-infected CoronaVac-vaccinated samples collected during 2020–2021, a period of minimal community transmission. Shaded areas indicate 95% confidence region. Red dot and cross represent the median sensitivity and specificity and corresponding confidence intervals of the OD threshold jointly estimated via Gibbs Sampling as described in Methods. Pos: positive controls, Neg: negative controls, Sens: sensitivity, Spec: specificity, AUC: area under the curve.
Extended Data Fig. 3 Description of controls, assay performance and Receiver Operating Curves (ROC) by ELISA assay type for detecting Omicron infection with in-house ELISA protocols. (a) N-CTD ELISA amongst unvaccinated controls, tested against 48 unvaccinated study subjects with self-reported infection history, 142 unvaccinated RT-PCR positive convalescent samples ranging from 30 to 401 days after onset of illness and 526 pre-pandemic negative controls; (b) N-CTD ELISA amongst controls who were homologously vaccinated with BNT162b2, tested against 881 BNT-vaccinated study subjects with self-reported infection history, 1 BNT-vaccinated RT-PCR positive convalescent sample collected 369 days after onset of illness and 50 (tested twice) non-infected BNT-vaccinated samples collected during 2020–2021, a period of minimal community transmission; and (c) ORF8 ELISA amongst controls who were homologously vaccinated with CoronaVac, tested against 231 CoronaVac-vaccinated study subjects with self-reported infection history and 100 non-infected CoronaVac-vaccinated samples collected during 2020–2021, a period of minimal community transmission. Shaded areas indicate 95% confidence region. Red dot and cross represent the median sensitivity and specificity and corresponding confidence intervals of the OD threshold jointly estimated via Gibbs Sampling as described in Methods. Pos: positive controls, Neg: negative controls, Sens: sensitivity, Spec: specificity, AUC: area under the curve.CC BY · PubMed Central
Extended Data Fig. 4 Vaccine effectiveness over time only including samples collected on or before 15 June 2022. VE at zero to 200 days from receipt of last dose. VE is presented separately over time for two, three or four homologous doses of BNT162b2 (BNT) or CoronaVac. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.
Extended Data Fig. 4 Vaccine effectiveness over time only including samples collected on or before 15 June 2022. VE at zero to 200 days from receipt of last dose. VE is presented separately over time for two, three or four homologous doses of BNT162b2 (BNT) or CoronaVac. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.CC BY · PubMed Central
Extended Data Fig. 5 Population immunity over time from vaccination and infection by age group assuming no waning of immunity from infection. Population immunity estimates among those aged 12–19 or aged 60 or above were less accurate as no subjects were between 12 and 17 years old, and few were above 65 years old. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.
Extended Data Fig. 5 Population immunity over time from vaccination and infection by age group assuming no waning of immunity from infection. Population immunity estimates among those aged 12–19 or aged 60 or above were less accurate as no subjects were between 12 and 17 years old, and few were above 65 years old. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.CC BY · PubMed Central
Extended Data Fig. 6 Population immunity over time from vaccination and infection by age group assuming immunity from infection wanes by 15% after 365 days. Population immunity estimates among those aged 12–19 or aged 60 or above were less accurate as no subjects were between 12 and 17 years old, and few were above 65 years old. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.
Extended Data Fig. 6 Population immunity over time from vaccination and infection by age group assuming immunity from infection wanes by 15% after 365 days. Population immunity estimates among those aged 12–19 or aged 60 or above were less accurate as no subjects were between 12 and 17 years old, and few were above 65 years old. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.CC BY · PubMed Central
Extended Data Fig. 7 Population immunity over time from vaccination and infection by age group assuming immunity from infection wanes by 25% after 100 days. Population immunity estimates among those aged 12–19 or aged 60 or above were less accurate as no subjects were between 12 and 17 years old, and few were above 65 years old. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.
Extended Data Fig. 7 Population immunity over time from vaccination and infection by age group assuming immunity from infection wanes by 25% after 100 days. Population immunity estimates among those aged 12–19 or aged 60 or above were less accurate as no subjects were between 12 and 17 years old, and few were above 65 years old. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.CC BY · PubMed Central
Extended Data Fig. 8 IAR over time by age group and assumptions on seroconversion rate among infected. All figures assumed a 7-day delay to VE taking effect. IAR estimates among those aged 12–19 or aged 60 or above were less accurate as no subjects were between 12 and 17 years old, and few were above 65 years old. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.
Extended Data Fig. 8 IAR over time by age group and assumptions on seroconversion rate among infected. All figures assumed a 7-day delay to VE taking effect. IAR estimates among those aged 12–19 or aged 60 or above were less accurate as no subjects were between 12 and 17 years old, and few were above 65 years old. The lines indicate posterior medians and shaded bars indicate 95% credible intervals based on the fitted model.CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 3 Not valid · 3 Not checked · 40 Own results and interpretations

38 more claims · 2 with their cited sources checked

Create a free account to see all 54 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 5
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 72 references

Research works printed but not linked: 1

  1. Modelling the Fifth Wave of COVID-19 in Hong Kong – Update #9 (The Univ. of Hong Kong, 2022); https://www.med.hku.hk/en/news/press//-/media/HKU-Med-Fac/News/slides/20220314-sims_wave_5_omicron_2022_03_14_final.ashx

Cited by

See all 205

Metadata

Authors
Lau, J. J., Cheng, S. M. S., Leung, K., Lee, C. K., Hachim, A., Tsang, L. C. H., Yam, K. W. H., Chaothai, S., Kwan, K. K. H., Chai, Z. Y. H., Lo, T. H. K., Mori, M., Wu, C., Valkenburg, S. A., Amarasinghe, G. K., Lau, E. H. Y., Hui, D. S. C., Leung, G. M., Peiris, M., & Wu, J. T.
Affiliations
  • Laboratory of Data Discovery for Health (HK)
  • University of Hong Kong (HK)
  • University of Hong Kong - Shenzhen Hospital (CN)
  • HKU-Pasteur Research Pole (HK)
  • Ishikawa Prefectural University (JP)
  • Washington University in St. Louis (US)
  • The University of Melbourne (AU)
  • Chinese University of Hong Kong (HK)
Corresponding author
Wu, Joseph T.
Venue
Nature Medicine
Published
2023-01-18
Volume
29
Issue
2
Pages
348-357
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4317209210
Cited by
198
References
72
Citations by year
2026: 27 · 2025: 42 · 2024: 77 · 2023: 52
FWCI
40.75
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • Figshare (submittedVersion)
Funders
  • Food and Health Bureau of the Government of the Hong Kong Special Administrative Region | Health and Medical Research Fund (COVID190126)
  • AIR@InnoHK, Innovation and Technology Commission, Government of the Hong Kong Special Administrative Region Theme based Research Grants Scheme, Hong Kong Special Administrative Region
  • University of Hong Kong
  • Theme based Research Grants Scheme, Hong Kong Special Administrative Region
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords
COVID-19 vaccine effectiveness, SARS-CoV-2, BNT162b2, CoronaVac, vaccine waning, serological survey, Hong Kong, booster vaccination
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, Vaccine Efficacy, BNT162 Vaccine, Humans, Vaccines, Inactivated

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. https://app.cochat.ai/papers/10.1038/s41591-023-02219-5
The paper
Lau, J. J., Cheng, S. M. S., Leung, K., Lee, C. K., Hachim, A., Tsang, L. C. H., Yam, K. W. H., Chaothai, S., Kwan, K. K. H., Chai, Z. Y. H., Lo, T. H. K., Mori, M., Wu, C., Valkenburg, S. A., Amarasinghe, G. K., Lau, E. H. Y., Hui, D. S. C., Leung, G. M., Peiris, M., & Wu, J. T. (2023). Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nature Medicine. https://doi.org/10.1038/s41591-023-02219-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.